Skip to main content
S 2910 117th Congress Senate Health Drug safety, medical device, and laboratory regulation Prescription drugs

Expanding Access to Low-Cost Generics Act of 2021

Introduced: September 30, 2021 Introduced by: Smith, Tina Democratic · Minnesota See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 20, 2021
Star Print ordered on the bill.
Sep 30, 2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sep 30, 2021
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Expanding Access to Low-Cost Generics Act of 2021

This bill modifies provisions related to market exclusivity for a generic drug.

Currently, the Food and Drug Administration (FDA) awards 180 days of exclusivity on the market to a first applicant to file a qualifying application for market approval of a generic drug. Generally, this exclusivity period begins upon a first applicant's commercial marketing of the drug.

The bill authorizes the FDA to approve a subsequent generic drug application prior to a first applicant's first date of commercial marketing if (1) the subsequent application is ready for full approval, (2) a first applicant's application has been pending for at least 30 months, (3) the approval of a first applicant's application is not precluded by patent infringement claims asserted against that first applicant, and (4) no first applicant's application has been effectively approved on the date that all such conditions are met.

What's happening now October 20, 2021

Star Print ordered on the bill.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 2910: Expanding Access to Low-Cost Generics Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-S-2910/
MLA
"S. 2910: Expanding Access to Low-Cost Generics Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-2910/.
Bluebook (legal)
S. 2910, 117th Cong. (2026), https://openamerica.io/bill/117-S-2910/.
Markdown link
[S. 2910: Expanding Access to Low-Cost Generics Act of 2021](https://openamerica.io/bill/117-S-2910/)
Report a problem